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Decision Making Under Uncertainty: 
Comparing Regulatory and Health Technology 
Assessment Reviews of Medicines in the 
United States and Europe
Rick A. Vreman1,2 , Huseyin Naci3,4 , Wim G. Goettsch1,2, Aukje K. Mantel-Teeuwisse1,* ,  
Sebastian G. Schneeweiss4 , Hubert G. M. Leufkens1  and Aaron S. Kesselheim4
Assessments of clinical evidence vary between regulators and health technology assessment bodies, but precise 
differences remain unclear. To compare uncertainties raised on the clinical evidence of approved drugs, we analyzed 
assessments of regulators and health technology assessment (HTA) bodies in the United States and Europe. We found 
that US and European regulators report uncertainties related to safety for almost all drugs (85–94%), whereas HTA 
bodies reported these less (53–59%). By contrast, HTA bodies raised uncertainties related to effects against relevant 
comparators for almost all drugs (88–100%), whereas this was infrequently addressed by regulators (12–32%). 
Regulators as well as HTA bodies reported uncertainties related to the patient population for 60–95% of drugs. The 
patterns of regulator-HTA misalignment were comparable between the United States and Europe. Our results indicate 
that increased coordination between these complementary organizations is necessary to facilitate the collection of 
necessary evidence in an efficient and timely manner.
Regulators must balance the size of clinical benefits of medicines 
against their harmful effects, taking into account uncertainties in 
both measures.1–4 After regulatory approval, use of a drug will de-
pend on its incremental clinically relevant effects in relation to al-
ready available treatments. Use will also depend on the willingness 
or ability to pay for the drug and coverage by insurers. The process 
of clinical and economic value assessment is formalized in Europe 
through evaluations by Health Technology Assessment (HTA) 
bodies. In the United States, it often relies on assessments of inde-
pendent clinicians or organizations, or individual insurance plans.
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Regulators evaluate the benefit-risk balance of drugs while 
health technology assessment (HTA) bodies evaluate drug ef-
fects compared with available alternatives. Approved drugs are 
often rejected for reimbursement by HTA bodies because of un-
certainties related to clinical evidence.
WHAT QUESTION DID THIS STUDY ADDRESS?
 This study quantified and compared the uncertainties that 
regulators and HTA bodies raise during their evaluations of 
clinical evidence.
WHAT DOES THIS STUDY ADD TO OUR KNOW- 
LEDGE?
 There is a clear, quantifiable gap in reported uncertainties 
between regulators and HTA bodies regarding clinical evidence 
on safety, effects vs. relevant comparators, and clinically rel-
evant, long-term outcomes. Both regulators and HTA bodies 
report uncertainties related to the patient population for a ma-
jority of assessed drugs. Differences in reported uncertainties 
between regulators and HTA bodies are similar between the 
United States and Europe.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 Increased coordination between regulators and HTA bodies 
may facilitate the collection of necessary evidence to resolve the 
demonstrated gaps in an efficient and timely manner, benefit-
ing patients’ access to drugs.
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Having to accept some uncertainties at approval is inherent 
to the limited information on benefits and risks available at the 
time of marketing authorization, but current trends suggest that 
drugs are being approved by regulators on the basis of testing in 
fewer patients and with fewer pivotal trials.5,6 In recent years, 
over two-thirds of all trials submitted to the US Food and Drug 
Administration (FDA) did not have an active comparator, and 
20% did not have a comparator at all.7 Furthermore, 59% of piv-
otal trials submitted to the FDA used surrogate measures as their 
primary trial end points.8 In Europe, only 35% of oncology indica-
tions approved by the European Medicines Agency (EMA) had ev-
idence of survival benefits over available treatments. Uncertainties 
relating to the evidence of newly approved drugs can remain unre-
solved for multiple years. With a median follow-up postapproval 
between 3 and 5.4 years, there was no evidence of survival benefits 
in 28–58% of approved oncology indications in the United States 
and Europe.9–14 Correlation of surrogate measures with survival is 
often low.15
Regulators and HTA bodies have key similarities in their evalu-
ations of new drugs, as they are usually based on the same clinical 
evidence. However, an important difference is that HTA bodies 
aim to evaluate effects against relevant comparators, whereas reg-
ulators evaluate a single treatment’s benefit-risk balance, which 
does not necessarily involve comparison to an active treatment. 
Additionally, the relevant comparators may differ between subsets 
of the approved population. This means that HTA bodies may dif-
fer in opinion from regulators about which populations will ben-
efit from the treatment. If no active comparator is available, HTA 
bodies evaluate drug effects against best supportive care, which 
may be different from the care provided in placebo-controlled clin-
ical trials. HTA bodies have repeatedly indicated that the evidence 
regulators find sufficient for establishing a positive benefit-risk bal-
ance can be too limited to accurately establish comparative effec-
tiveness and value.16–23
Because most new drugs are now being evaluated by regulators 
and HTA bodies in the United States and Europe, it is important 
to know whether—and how—these reviews agree or disagree in 
their assessment of a drug. We, therefore, sought to investigate and 
quantify the uncertainties that regulators and HTA bodies raise 
during their evaluations of clinical evidence.
METHODS
Sample construction
To perform a pairwise comparison between regulatory and HTA eval-
uations in the United States and Europe, we included medicines ap-
proved by the FDA and the EMA that were subsequently assessed by 
HTA bodies in both jurisdictions. In the United States, where there 
is no national HTA body, the Institute for Clinical and Economic 
Review (ICER) was used as the HTA body of choice. ICER is an inde-
pendent organization that conducts HTAs on a selection of high-im-
pact and high-profile drugs and drug classes. Included European 
HTA bodies were the Institute for Quality and Efficiency in Health 
Care (IQWiG, Germany), the National Institute for Health and 
Care Excellence (NICE, England and Wales), the National Health 
Care Institute (ZIN, The Netherlands), as well as the collaborative 
European network for HTA (EUnetHTA). EUnetHTA is not an 
HTA body itself but a consortium of HTA bodies that collaborate 
on, among others, joint assessments. These HTA bodies were selected 
because they provided comprehensive public reports in languages un-
derstood by the investigators (English and Dutch). The final cohort 
consisted of all EMA and FDA-approved new drugs (i.e., excluding 
generics and biosimilars) that were subsequently evaluated by ICER 
and at least two of the four included European HTA bodies. Reports 
must have been published between January 1, 1995, and December 31, 
2018. Data from reports of European HTA bodies were combined into 
an aggregated European HTA database (AGGR-EUR).
Data sources
Although the regulatory and HTA bodies in the study had different 
evaluation processes, the key document used was the one summarizing 
the pivotal trials supporting a drug’s clinical utility. Included sections of 
final reports were all those in which an interpretation of the clinical ev-
idence was provided by the evaluating entity. We excluded sections that 
did not relate to clinical evidence or that summarized clinical evidence 
without interpretation, as well as cost-effectiveness sections. The reports 
used, including the relevant sections and subsections, are outlined in the 
Supplementary Table S1.
Outcome measurements
From the relevant sections of the reports for each drug in the cohort, 
“uncertainties” related to the clinical evidence were extracted with 
NVivo 12.24 An uncertainty was defined as any piece of text that ex-
plicitly or implicitly reported an unresolved shortcoming, question, 
or issue in the clinical evidence. Only unresolved uncertainties were 
extracted; thus, it would not count as an uncertainty if the report 
pointed out missing data on a subgroup, but it later turned out that 
the subgroup was not clinically relevant because the drug was not ap-
proved for that subgroup. An example of an explicit uncertainty would 
be the reporting of insufficient long-term data to interpret adverse 
events. An example of an implicit uncertainty would be a statement 
saying the only reported outcome was an unvalidated laboratory test, 
as this implies the lack of a clinically relevant outcome. Within the 
analysis, no distinction was made between implicit or explicit uncer-
tainties. Uncertainties mentioned within the same report on multiple 
occasions were included once. For some drugs, HTA bodies published 
a report on a whole drug class or indication rather than per drug. If an 
uncertainty within those reports was about the drug class or about all 
drugs within the indication (e.g., a lack of any comparative data), that 
uncertainty was included for each drug separately.
In addition, basic regulatory characteristics were collected about ap-
proval date, expedited approval pathways, special rare disease treatment 
status (e.g., via the Orphan Drug Act), and evidence considered for evalu-
ation (control arm and end points).
Analysis
Uncertainties were classified into six categories related to safety, ef-
ficacy, and effectiveness (Table 1). The first category included all 
uncertainties related to safety. The second category encompassed all 
uncertainties concerning the validity of the clinical trial results (ef-
ficacy). The rest of the categories were dedicated to the generalizabil-
ity of the outcomes (effectiveness) observed in the assessed trials and 
related to the relevance of the studied patient population, the appli-
cability of the intervention in practice, the drug’s effects in relation 
to relevant comparators, and the clinical relevance and long-term 
effects of the studied outcomes. If an uncertainty originated from 
one category (e.g., trial validity) but only applied to a specific other 
category (e.g., a specific outcome or subgroup), this uncertainty was 
assigned to the category of its application and not the category of its 
origin. An example is the effect of crossover on long-term extension 
trials. Crossover relates to trial validity, but only affects the specific 
outcome of long-term results and was, thus, assigned to the outcomes 
category. The assignment of all uncertainties to categories was done 
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independently and in duplicate by two investigators (R.A.V. and H.N.; 
kappa statistic: 0.85), discussing discrepancies until reaching consen-
sus. Statistical significance of differences in the number of reported 
uncertainties was assessed via t-tests.
After all uncertainties were assigned a category, we analyzed the align-
ment of regulators and HTA bodies within each jurisdiction (United 
States/Europe) by comparing per category the percentage of drugs for 
which both stakeholders reported at least one uncertainty. Uncertainties 
were extracted for each of the four included European HTA bodies, but 
for the European comparative analysis of regulator vs. HTA body, all un-
certainties of the four institutions were combined and duplicates were 
removed. This resulted in an AGGR-EUR. Differences between reg-
ulators and HTA bodies were expressed as misalignment per category. 
Misalignment per category was defined as the percentage of drugs for 
which one stakeholder reported at least one uncertainty within the cate-
gory, but the other stakeholder reported none.
Subgroup analyses
Six subgroup analyses were performed on the differences between 
regulators and HTA bodies. The subgroups included drugs approved 
by regulators using surrogate measures as primary end points, drugs 
approved based on pivotal trials without active control arms, drugs 
approved with special designations for treating rare diseases, drugs 
approved with at least one expedited testing or regulatory review 
designation, drugs that were first-in-class, and drugs approved before 
December 2013 (5 years before inclusion end date). Previous research 
has highlighted the presence of clinical uncertainties in these sub-
groups.25–29 Expedited designations included fast-track, accelerated 
approval, breakthrough status, and priority review for the United 
States, as well as conditional marketing authorization and accelerated 
assessment for Europe.
RESULTS
Evaluations were available for 33 drugs, covering 34 indica-
tions. Characteristics of the included indications are provided in 
Table 2. Over half were antineoplastic or immunomodulatory 
agents. Almost half benefited from at least one expedited pathway 
in the United States, whereas only seven benefited from such a 
pathway in Europe (44% vs. 21%). In the United States, there were 
12 drugs (35%) qualifying for fast-track procedures, 4 (12%) for ac-
celerated approvals, 5 drugs (15%) for breakthrough status, and 12 
drugs (35%) for priority review. In Europe, one drug (3%) received 
a conditional marketing authorization and six drugs (18%) qual-
ified for accelerated assessment. In most cases, the evidence base 
available for review was similar between regulators, but there were 
four cases in which the FDA approved drugs earlier than the EMA 
and with more limited evidence. No European HTA body assessed 
all 34 indications. The IQWiG (Germany) assessed 26 (76%) in-
dications, NICE (England + Wales) assessed 33 (97%), ZIN (The 
Netherlands) assessed 18 (53%), and EUnetHTA (Europe) assessed 
4 (12%) indications.
Number of reported uncertainties
In total, 1,121 uncertainties were identified in assessment reports 
for all included drugs. Examples of extracted uncertainties for one 
of the drugs (evolocumab) are presented in Table 3. When aggre-
gating European HTA organizations, after removal of duplicates, 
a total of 1,007 uncertainties remained for all institutions. Of 
those, the FDA raised 149 uncertainties, the ICER 286, EMA 250, 
and the combined European HTA bodies (AGGR-EUR) raised 
322 uncertainties. At least one uncertainty was reported for each 
assessed drug by each institution. An average of 7.4 uncertainties 
(SD 3.8) were raised per drug per institution. Figure 1 shows the 
Table 1 Categories of uncertainties and examples of the 
types of uncertainties that were assigned to each category
Category name Examples of the types of uncertainties
Safety issues Safety sample size too small
Causality of adverse events uninterpretable
Long-term safety unclear
Trial validity Selection bias
Performance bias
Detection bias
Attrition bias
Reporting bias
Population Population does not match practice
Relevant subgroups not adequately studied or 
reported
Intervention Unreliable or missing information on 
interactions with other medication
Unreliable or missing information on 
 monotherapy or combination regimens
Unreliable or missing information on 
 appropriate treatment duration
Comparators Unreliable or missing information on effects 
against relevant comparators
Unreliable indirect comparisons
Unreliable or missing information on 
 appropriate treatment line
Outcomes Unreliable or missing information on long-term 
effects
Relevant outcomes not measured or reported
Table 2 Basic characteristics of the 34 included indications
Therapeutic class Number of indications (%)
Alimentary tract and metabolism 2 (6)
Cardiovascular system 3 (9)
Dermatological 1 (3)
Anti-infective 4 (12)
Antineoplastic or immunomodulatory 20 (59)
Respiratory system 3 (9)
Sensory organs 1 (3)
Subgroup United States Europe
Approved with at least one special 
regulatory designation
15 (44) 7 (21)
Rare disease designation status 7 (21) 2 (6)
Approved on surrogate primary end 
points
7 (21) 6 (18)
Active control pivotal trial not 
available
18 (53) 15 (44)
First-in-class 17 (50) 17 (50)
Approved > 5 years ago 22 (65) 21 (62)
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distributions of uncertainties per assessed drug for regulators and 
HTA bodies in the United States and Europe. The FDA raised, on 
average, 4.4 (SD: 2.2) uncertainties per drug, ICER raised 8.4 (SD: 
2.6). The mean difference was 4.2 uncertainties per drug (P < 0.01). 
The EMA raised an average of 7.4 (SD: 3.6) uncertainties per drug, 
the aggregated European HTA bodies raised 9.5 (SD: 4.4). The 
mean difference was 2.1 uncertainties per drug (P = 0.02).
Categories of reported uncertainties
Figure 2 shows the percentage of drugs by category for which at 
least one uncertainty was raised (solid bars). Additionally, Figure 2 
indicates the percentage of drugs within the respective categories 
for which only one stakeholder (either regulator or HTA body) 
within a jurisdiction raised uncertainties and the other stake-
holder did not (translucent bars).
Safety issues—such as those related to sample size or uncertain-
ties in causality—were raised by regulators for almost all drugs 
assessed (94% for the FDA and 85% for the EMA). HTA bodies 
raised safety issues for only 59% (ICER) and 53% (AGGR-EUR) 
of drugs. Thus, for 35% (United States) and 32% (Europe) of 
drugs, regulators, and HTA bodies were not aligned with respect 
to reporting uncertainties related to safety.
HTA bodies raised uncertainties related to effects against relevant 
comparators for almost all drugs (100% in the United States and 88% 
in Europe), whereas this category was hardly addressed by the FDA 
(12%) and only slightly more by the EMA (32%). Misalignment 
between regulators and HTA bodies was present for 88% (United 
States) and 56% (Europe) of indications, respectively. Uncertainties 
related to the relevance of the end points considered and long-term 
effects were also raised for more drugs by HTA bodies than by regu-
lators (82% and 91% for ICER and AGGR-EUR, respectively, and 
41% and 62% for the FDA and EMA, respectively). There was mis-
alignment in 41% (United States) and 29% (Europe) of indications.
The percentages of indications for which uncertainties were 
raised related to the categories of patient population and interven-
tion applicability were similar between regulators and HTA bodies. 
The percentage of indications with raised uncertainties related to 
trial validity was similar between the FDA and ICER but differed 
more between the EMA and the aggregated European HTA bod-
ies: Misalignment was present for 12% of indications in the United 
States and for 32% of indications in Europe. All stakeholders raised 
uncertainties related to the patient population for > 60% of assessed 
drugs.
Table 3 Examples of uncertainties extracted from the 
regulatory and health technology assessment reports for 
evolocumab
Safety category: The trials were 6 months or less in duration. 
Serious adverse events may be identified in the large 5-year out-
come trials that are currently in progress
Population category: The overall trial population does not represent a 
population at high cardiovascular risk with substantial cardiovascular 
disease burden on maximally tolerated statin therapy, arguably the 
most appropriate patient population for add-on therapy to a statin
Comparators category: No valid comparison was available with 
ezetimibe, evolocumab was only compared with placebo or stand-
ard of care
Outcomes category: The RCTs primarily measured surrogate end 
points (such as LDL-C) and were not powered to measure cardiovas-
cular outcomes, which was considered to be an important limita-
tion of the evidence base
LDL-C, low-density lipoprotein cholesterol; RCTs, randomized controlled trials.
Figure 1 Distribution of the number of uncertainties raised per drug as reported by the United States and European regulators and health 
technology assessment bodies. The horizontal lines indicate the medians and the boxes indicate the interquartile range. Single points indicate 
outliers. AGGR-EUR, aggregated European HTA database; EMA, European Medicines Agency; FDA, US Food and Drug Administration; ICER, 
Institute for Clinical and Economic Review.
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Overall, the patterns of differences between regulators and 
HTA bodies were very similar between the United States and 
Europe.
Subgroup analyses
Figure 3 shows the percentage of total categories throughout 
all indications in which uncertainties were raised by each stake-
holder overall and in the predefined subgroups. The FDA re-
ported uncertainties in 40% of all categories and ICER in 62%. 
The EMA reported uncertainties in 56% of categories and the 
European HTA bodies in 72%. None of the subgroups showed 
statistical differences in number of categories with uncertain-
ties that were or were not raised by one of the stakeholders. 
Some of the subgroups were small (Table 2) and the subgroup 
results were confounded by indication; for example, only two 
rare disease drugs were included for Europe and all anti-infec-
tive drugs in our sample received priority review (FDA) or accel-
erated assessment (EMA).
Figure 2 Percentage of drugs for which stakeholder raised uncertainties, by category. Blue is for regulators, orange for health technology 
assessment (HTA) bodies. Solid bars indicate drugs for which both stakeholders raised uncertainties within that category, translucent bars 
indicate drugs for which only one stakeholder raised uncertainties (e.g., blue translucent bars indicate the percentage of indications for which 
regulators reported uncertainties but HTA bodies did not). AGGR-EUR, aggregated European HTA database; EMA, European Medicines Agency; 
FDA, US Food and Drug Administration.
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DISCUSSION
In this systematic analysis of assessment reports from regulators 
and HTA bodies in the United States and Europe, many of the 
uncertainties raised by regulators on safety were not mirrored in 
HTA processes, whereas regulators did not report the majority of 
uncertainties raised by HTA bodies related to effects against rel-
evant comparators and long-term clinically relevant effects. In a 
majority of indications, both regulators and HTA bodies reported 
remaining uncertainties related to multiple drug features. The 
differences between regulators and HTA bodies have similar pat-
terns in the United States and Europe.
Policy implications
The results of this study reflect the different objectives that drive 
the evaluations of regulators and HTA bodies. Regulators often 
make a judgment about a drug’s benefit-risk balance without ac-
tive-controlled trials or trials confirming a clinically relevant long-
term effect, particularly if known side effects are relatively mild 
or can be managed. However, such data naturally provide HTA 
bodies with little information on incremental benefit over exist-
ing treatments.23 Thus, there is a gap between the evidence that 
is sufficient for regulators to assess benefits and harms, and the 
evidence that HTA bodies require to evaluate effects against rele-
vant comparators, which we quantified through the differences in 
reported uncertainties.
Currently, only regulators have the authority to determine the 
quality and size of the pre-approval clinical evidence package 
deemed appropriate for decision making and any additional stud-
ies that are required postapproval. Although previous studies have 
recognized that postapproval testing commitments recommended 
by regulators are often changed, delayed, or not fulfilled, it is also 
true that most of these postapproval obligations are not intended 
to increase insight into comparative or clinically relevant long-term 
effects.9–12,18,20,30–32 Although some HTA bodies in Europe may 
ask for additional studies, most HTA bodies do not have the au-
thority to compel these trials to be completed.
To address the gap in reported uncertainties between regu-
lators and HTA bodies, these groups could coordinate better 
when setting postapproval testing recommendations. For ex-
ample, regulators from the EMA have recently indicated their 
awareness of the fact that a positive benefit-risk decision does 
not necessarily translate to relative benefit and have indicated 
Figure 3 Percentage of categories throughout all indications with raised uncertainties overall and in each of the subgroups. Darker gray is for 
regulators, lighter gray for health technology assessment bodies. Solid bars indicate the percentage of categories throughout all indications 
in which both stakeholders raised uncertainties, translucent bars indicate the percentage in which only one stakeholder raised uncertainties. 
AGGR-EUR, aggregated European HTA database; EMA, European Medicines Agency; ERP, expedited regulatory pathway; FDA, US Food and 
Drug Administration; ICER, Institute for Clinical and Economic Review.
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their intent to be more explicit about negative, neutral, or pos-
itive added benefit in relevant patient subgroups.33 A first step 
for regulators may be to collaborate with HTA bodies and other 
stakeholders in the development process to start identifying the 
uncertainties that are relevant to downstream stakeholders and 
to discuss the necessary evidence and timing of its generation. 
Joint scientific advice procedures may benefit the generation 
of evidence that resolves the most important uncertainties for 
both stakeholders. Previous research has shown that regulators 
and HTA organizations reached a high level of agreement in 
evidence requirements during joint scientific advice procedures. 
Industry tended to implement changes to the development pro-
gram in terms of primary end points and comparators based on 
feedback from both stakeholders.34,35 The process of joint scien-
tific advice is now formalized in Europe between the EMA and 
EUnetHTA and is called parallel consultation.
HTA bodies often did not raise the same uncertainties that reg-
ulators reported related to safety. This is interesting because usually 
HTA bodies have regulatory reports readily available during their 
evaluation process, and they often refer to findings discussed by 
regulators. The lack of alignment on uncertainties related to safety 
suggests that HTA bodies do not systematically re-assess safety and 
instead rely on a positive benefit-harm assessment, or do not find 
such uncertainties relevant enough to report them. However, for 
the determination of added benefit, as for the benefit-risk balance, 
an inappropriately sized safety database or potentially increased 
safety risks have important implications. Further study is needed 
on how HTA bodies assess drug safety and integrate those assess-
ments into their determinations.
There were some similarities in the uncertainties raised by 
regulators and HTA bodies. Both regulators and HTA bodies 
raise uncertainties related to the generalizability of the trial 
population and a lack of reliable information for important sub-
groups in 65–97% of indications. By definition, the majority of 
approved drugs have unresolved uncertainties related to how 
clinical trial effects will translate to patients who will use the 
drug in practice. All stakeholders, including clinicians and pa-
tients, could benefit from a coordinated effort to prospectively 
define the patient subgroups that need to be studied more exten-
sively postapproval.
Limitations
The inclusion of drugs approved by both regulators and re-
viewed by ICER and at least two European HTA bodies may 
have caused selection bias. This selection procedure was nec-
essary to provide a comparison between the United States and 
Europe, but, therefore, cannot be extrapolated to other drugs. 
However, the distribution of drugs in the cohort ref lect recent 
approval trends and we found no evidence of modification of 
differences by any of the subgroups, although subgroup sample 
sizes were often small and differences were confounded by other 
factors.
The included reports differed in timing. Thus, some uncertain-
ties reported by regulators may have been resolved at the time of 
HTA. However, this effect is at most minor and will not influence 
the conclusions related to effects against relevant comparators 
and clinically relevant outcomes because uncertainties were raised 
by HTA bodies for almost all drugs within these categories. Size 
and detail of reports also differed, including the option for HTA 
bodies to perform assessments at the drug-class or indication level. 
We assumed that all relevant uncertainties were reported.
We chose to combine uncertainties raised by multiple institu-
tions into an aggregated European HTA dataset. This increases 
the validity of the United States vs. Europe comparison, but also 
means results do not necessarily apply to each individual HTA 
jurisdiction in Europe. Because HTA bodies do not always raise 
the same uncertainties, the misalignment between the EMA 
and individual HTA bodies may differ from the aggregated set. 
Nevertheless, for pre-approval and postapproval evidence genera-
tion within Europe, uncertainties raised by any of the HTA bodies 
are relevant, which makes our method of comparison the most ap-
propriate one.
CONCLUSION
In the United States as well as in Europe, in order to fulfill their 
respective decision-making mandates, some overlap exists in evi-
dence needs between regulators and HTA bodies, but there is also 
substantial discordance, particularly regarding drug safety, drug ef-
fects vs. appropriate comparators, and the suitable time horizon for 
effects on relevant outcomes. Increased coordination between these 
two important, complementary organizations may facilitate the 
collection of necessary evidence in an efficient and timely manner.
SUPPORTING INFORMATION
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